Vaxcyte is a biotech vaccine company that develops protein-based vaccines for bacterial infectious diseases, including VAX-24, a 24-valent vaccine candidate for pneumococcal disease in Phase 1/2 trials. Additionally, the company develops vaccines to address emerging strains, antibiotic resistance, Group A Strep, and periodontitis. Formerly known as SutroVax, the company was founded in 2013 and is based in San Carlos, California.